التفاصيل البيبلوغرافية
| العنوان: |
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. |
| المؤلفون: |
Yang, James Chih-Hsin, Han, Baohui, De La Mora Jiménez, Emmanuel, Lee, Jong-Seok, Koralewski, Piotr, Karadurmus, Nuri, Sugawara, Shunichi, Livi, Lorenzo, Basappa, Naveen S., Quantin, Xavier, Dudnik, Julia, Ortiz, Diego Moran, Mekhail, Tarek, Okpara, Chinyere E., Dutcus, Corina, Zimmer, Zachary, Samkari, Ayman, Bhagwati, Niyati, Csőszi, Tibor |
| المصدر: |
Journal of Thoracic Oncology; Jun2024, Vol. 19 Issue 6, p941-953, 13p |
| قاعدة البيانات: |
Complementary Index |
